Mubadala Investment Company has announced that it has acquired 100% ownership in UCB Pharma's mature business in China in partnership with CBC Group, Asia's largest dedicated healthcare asset management group.

According to Amac News: Mubadala's announcement states that UCB is a global biopharmaceutical company headquartered in Belgium and has taken a leading position in the market.
According to the announcement, the scope of the acquisition includes UCB's neurology portfolio (Keppra®, Vimpat®, Neupro®) and allergy portfolio (Zyrtec®, Xyzal®) in mainland China, as well as UCB's Zhuhai manufacturing site. In 2023, the total net sales of these drugs in China will be 131 million euros.
The announcement emphasized that the investment is in line with Mubadala's vision to expand its footprint across Asia through selective investment in various sectors with strong growth potential.
Healthcare, and pharmaceuticals in particular, are at the forefront of this investment strategy. In addition, the strategic partnership with CBC Group, following the acquisition of Hasten Biopharma, underscores Mubadala's ongoing commitment to building proprietary platforms to target and serve unmet needs in China and the broader Asian healthcare markets.